ArticleFrontiers in pharmacology2025

Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis.

Jiefeng Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.